72.11.Z - Research and experimental development on biotechnology
21.20.Z - Manufacture of medicines and other pharmaceutical products
46.46.Z - Wholesale of pharmaceutical goods
68.10.Z - Buying and selling of own real estate
72.19.Z - Other research and experimental development on natural sciences and engineering
86.90.D - Paramedical activities
2021 | 2022 | ||
---|---|---|---|
M PLN | M PLN | % | |
Gross profit (loss) | -0 | 0,1 | 205 |
EBITDA | -0 | 0,1 | 207,4 |
Short time liabilities | 0,3 | 0,2 | -41,1 |
Equity capital | -0,7 | -0,6 | 7,3 |
Operating profit (EBIT) | -0 | 0,1 | 205 |
Assets | 0,8 | 0,8 | -3,7 |
Net profit (loss) | -0 | 0,1 | 205 |
Cash | 0 | 0 | 372,1 |
Net income from sale | 0 | 0 | -100 |
Liabilities and provisions for liabilities | 1,5 | 1,4 | -5,4 |
Working assets | 0,8 | 0,8 | -3,7 |
Depreciation | 0 | 0 | -100 |
% | % | p.p. | |
Profitability of capital | 7,1 | -8 | -15,1 |
Equity capital to total assets | -83,2 | -80 | 3,2 |
Gross profit margin | -8053 | ||
EBITDA Margin | -7870 | ||
Days | Days | Days | |
Short term commitment turnover cycle | 162 903 | 2 147 483 648 | 2 147 320 745 |
Current financial liquidity indicator | 0.5459397435188293 | 0.5554085373878479 | 0,1 |
Net dept to EBITDA | 0.02699040062725544 | -0.11863960325717926 | -0,1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane